Warfarin, aspirin, or both after myocardial infarction

Hurlen, Mette; Abdelnoor, Michael; Smith, Pål; Erikssen, J; Arnesen, Harald

doi:10.1016/s1062-1458(02)00990-x

Cited by 244 publications

(317 citation statements)

References 0 publications

Supporting

Mentioning

286

Contrasting

Unclassified

Order By: Relevance

“…18,19,30 The suggested protective effect of warfarin on the risk of myocardial infarction is not restricted to AF patients, and previous studies in patients with previous myocardial infarction have found warfarin to confer a better protection against reinfarction than aspirin. 45 However, in this study, patients on warfarin were at increased risk of bleeding compared to aspirin. 45 In the article by van Walraven et al, 46 among AF patients the risk of vascular events increased with increasing age ( ≥ 65 years), and the absolute benefit of oral anticoagulation therapy compared to control/placeboalso increased with increasing age, whereas the absolute benefit of antiplatelet therapy declined.…”

Section: Antithrombotic Therapy In Atrial Fibrillation Plus Vascular mentioning

confidence: 58%

“…45 However, in this study, patients on warfarin were at increased risk of bleeding compared to aspirin. 45 In the article by van Walraven et al, 46 among AF patients the risk of vascular events increased with increasing age ( ≥ 65 years), and the absolute benefit of oral anticoagulation therapy compared to control/placeboalso increased with increasing age, whereas the absolute benefit of antiplatelet therapy declined. A similar pattern was seen for stroke, 46 but the magnitude of absolute benefit was less compared to that seen for vascular events.…”

Section: Antithrombotic Therapy In Atrial Fibrillation Plus Vascular mentioning

confidence: 58%

See 1 more Smart Citation

Atrial Fibrillation and Vascular Disease—A Bad Combination

Olesen

Gislason

Torp‐Pedersen

et al. 2012

Clinical Cardiology

View full text Add to dashboard Cite

This article provides an overview of (i) the risk of stroke associated with vascular disease (acute coronary syndromes and peripheral artery disease) in patients with atrial fibrillation, (ii) the frequent coexistence of vascular disease in patients with atrial fibrillation and, (iii) the cardiovascular risk associated with the coexisting of the two diseases. The literature on this topic is relatively sparse, and we discuss results from both clinical trials and observational studies.There is a clear indication of an increased stroke risk associated with vascular disease in patients with atrial fibrillation. Indeed, patients with atrial fibrillation often had coexisting vascular disease (around 18%), and the combination of the two diseases substantially increases the risk of future cardiovascular events. The increased risk associated with peripheral artery disease in atrial fibrillation is even more pronounced.Patients with atrial fibrillation and stable vascular disease should be treated with oral anticoagulation only, although when these patients present with acute coronary syndrome and/or undergo coronary stenting, concomitant treatment with antiplatelet drugs is indicated. To guide antithrombotic management in patients with atrial fibrillation, several stroke and bleeding risk prediction schemes have been developed. Clin. Cardiol. 2012 DOI: 10.1002/clc.20955Dr. Olesen received an honorarium through an educational grant from Sanofi Aventis for time and expertise spent writing this article. Dr Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola and Boehringer Ingelheim and has been on the speakers bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi‐Aventis. Drs. Gislason and Torp‐Pedersen disclose no conflicts of interest.

show abstract

Section: Antithrombotic Therapy In Atrial Fibrillation Plus Vascular mentioning

confidence: 58%

Section: Antithrombotic Therapy In Atrial Fibrillation Plus Vascular mentioning

confidence: 58%

Atrial Fibrillation and Vascular Disease—A Bad Combination

Olesen

Gislason

Torp‐Pedersen

et al. 2012

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…Det er velkjent at antikoagulasjonsbehandling med warfarin i tillegg til platehemmere gir faerre nye iskemiske hendelser ved koro- narsykdom, men kombinasjonen medfører en betydelig blødningsrisiko (15). De nye antikoagulasjonsmidlenes rolle etter akutt koronarsyndrom er omdiskutert.…”

Section: Nye Antikoagulasjonsmidler Ved Akutt Koronarsyndromunclassified

Nye antikoagulasjonsmidler i kombinasjon med platehemmere

Johansen¹,

Rutherford²,

Aamodt³

et al. 2016

Tidsskriftet

View full text Add to dashboard Cite

“…Finally, because of the higher prevalence of cardiovascular diseases in elderly patients, they are more likely to be on antiplatelet agents (APA) at the time of PE diagnosis. Unless there is an absolute indication to APA such as recent coronary stents, transient discontinuation of APA during the AC period should in our opinion be considered on a case-by-case basis in order to reduce haemorrhagic risk, as the benefit of such a combination in terms of cardiovascular outcomes has not been proven [69,70].…”

Section: General Considerations On Therapeutic Anticoagulation In Eldmentioning

confidence: 99%

Diagnosis and management of pulmonary embolism in the elderly

Robert‐Ebadi

Righini

2014

European Journal of Internal Medicine

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oElderly patients are a population not only at particularly high risk of venous thromboembolism including pulmonary embolism (PE), but also at high risk of adverse clinical outcomes and treatment-related complications. Major progresses have been achieved in the diagnosis and treatment of PE over the last two decades. Nevertheless, some of elderly patients' specificities still represent important challenges in the management of PE in this population, from its suspicion to its diagnosis and treatment, and are discussed in this review. Perspectives for the future are from a diagnostic point of view the potential implementation of age-adjusted D-dimer cut-offs that will allow ruling out PE in a greater proportion of elderly patients without the need for thoracic imaging. From a therapeutic point of view, acquisition of post-marketing clinical experience with the use of new oral anticoagulants is still necessary, and in the meantime, these drugs should be prescribed with great caution in thoroughly selected elderly patients.

show abstract

Warfarin, aspirin, or both after myocardial infarction

Cited by 244 publications

References 0 publications

Atrial Fibrillation and Vascular Disease—A Bad Combination

Atrial Fibrillation and Vascular Disease—A Bad Combination

Nye antikoagulasjonsmidler i kombinasjon med platehemmere

Diagnosis and management of pulmonary embolism in the elderly

Contact Info

Product

Resources

About